The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

DexCom Q4 results are likely to reflect strong growth on the back of U.S. sales expansion, global gains and Stelo traction, ...

While short-term factors such as above-average reimbursement rates for its G7 CGM device ... its top and bottom lines, investors could reap long-term rewards. As an investor in DexCom myself ...

There will be an additional pool of potential users who are not insulin-dependent but would like to use a wearable like Stelo or G7, but in order to meet this demand, Dexcom may have to adjust its ...

Tandem Diabetes' t:slim X2 insulin pump is now compatible with Dexcom G7 CGM in Canada ... times is generally […] Tandem Diabetes' top and bottom lines outpace estimates in the third quarter ...

Dexcom (Nadsaq:DXCM) shares fell after hours today on fourth-quarter results that came in mixed compared to the consensus forecast.

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...

DXCM earnings call for the period ending December 31, 2024.

SAN DIEGO - DexCom , Inc. (NASDAQ:DXCM) shares fell 6% in after-hours trading on Thursday after the continuous glucose monitoring systems maker reported fourth-quarter earnings that missed analyst ...